BAALC and ERG Expression in Egyptian Patients with Acute Myeloid Leukemia, Relation to Survival and Response to Treatment
DOI:
https://doi.org/10.3889/oamjms.2016.058Keywords:
BAALC, ERG, gene expression, Quantitative real-time RT-PCR, AMLAbstract
AIM: Aim was to detect Brain and Acute Leukemia, Cytoplasmic (BAALC) and ETS-related gene (ERG) expression in patients with acute myeloid leukemia (AML) as well as to study their biologic and prognostic impact on the disease outcome and survival.
PATIENTS AND METHODS: The current study was carried out on 44 patients with denovo acute myeloid leukemia, as well as 44 age and sex matched controls. The quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) assay was performed for estimation of BAALC and ERG expression.
RESULTS: The current study was carried out on 44 patients with denovo acute myeloid leukemia, as well as 44 age and sex matched controls. The quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) assay was performed for estimation of BAALC and ERG expression. BAALC was expressed in 36 (81.82%) of AML cases versus 10 (22.72%) of the control group which was highly statistically significant (P < 0.001). While ERG was positive in 39(88.64%) of cases and 8(18.18 %) of controls and that was also highly statistically significant (P < 0.001).
CONCLUSION: Further researches still needed to clarify the role of BAALC and ERG in the pathogenesis of leukemia and their importance as targets for treatment of AML.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18: 115–136. http://dx.doi.org/10.1016/S0268-960X(03)00040-7
Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249–1259. http://dx.doi.org/10.1056/NEJMoa0904544 PMid:19776406 PMCid:PMC4480917
Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol. 2010;28:586-95. http://dx.doi.org/10.1200/JCO.2009.22.9088 PMid:20038732
Slovak ML, Kopecky KJ, Cassileth PA. Karyotypic analysis predicts outcome of pre remission and post remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-4083. PMid:11110676
Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ et al. Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council.AML11 trial. Blood. 2001;98:1312-1320. http://dx.doi.org/10.1182/blood.V98.5.1312 PMid:11520776
Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic. Cancer Res. 1998;4173-4179. PMid:9751631
Scheijen B & Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002;21: 3314–3333. http://dx.doi.org/10.1038/sj.onc.1205317 PMid:12032772
Baldus CD, Tanner SM, Kusewitt DF, Liyanarachchi S, Choi C, Caligiuri MA et al. BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol. 2003;31(11):1051-6. PMid:14585369
Downing JR. AML1/CBFb transcription complex: its role in normal hematopoiesis and leukemia. Leukemia.2001;15:664–665. http://dx.doi.org/10.1038/sj.leu.2402035 PMid:11368373
Baldus CD, Burmeister T, Martus P, Schwartz S, Gökbuget N, Bloomfield CD, et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol. 2006;24:790-797. http://dx.doi.org/10.1200/JCO.2005.01.6253 PMid:16418499
Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K et al. Cancer and Leukemia Group B (CALGB). High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008;111: 5371–5379. http://dx.doi.org/10.1182/blood-2007-11-124958 PMid:18378853 PMCid:PMC2396728
Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol. 2009;27: 5031–5038. http://dx.doi.org/10.1200/JCO.2008.20.5328 PMid:19752345
Bienz M, Ludwig M, Leibundgut EO. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005;11:1416-24. http://dx.doi.org/10.1158/1078-0432.CCR-04-1552 PMid:15746041
Bing Xu, Guoshu Chen, Pengcheng Shi. ShRNA - Mediated BAALC knockdown affects proliferation and apoptosis in human acute myeloid leukemia cells. Hematology. 2012;17:35-40. http://dx.doi.org/10.1179/102453312X13221316477499 PMid:22549446
Austin JL, Leone G. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci USA. 2001;98(24):13901–13906. http://dx.doi.org/10.1073/pnas.241525498 PMid:11707601 PMCid:PMC61139
Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood. 2003;102:1613–1618. http://dx.doi.org/10.1182/blood-2003-02-0359 PMid:12750167
Taoudi S, Bee T, Hilton A, et al. ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification. Genes Dev. 2011;25: 251-62. http://dx.doi.org/10.1101/gad.2009211 PMid:21245161 PMCid:PMC3034900
Baldus CD, Liyanarchchi S, Mro´zek K, Auer H, Tanner SM, Guimond M, et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2 and ERG genes. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:3915-3920. http://dx.doi.org/10.1073/pnas.0400272101 PMid:15007164 PMCid:PMC374344
Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23: 9234–9242. http://dx.doi.org/10.1200/JCO.2005.03.6137 PMid:16275934
Baldus CD, Burmeister T, Martus P, Schwartz S, Gökbuget N, Bloomfield CD et al. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol. 2006; 24: 4714–4720. http://dx.doi.org/10.1200/JCO.2006.06.1580 PMid:16954520
Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162–165. http://dx.doi.org/10.1038/359162a0 PMid:1522903
Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t (21; 22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994;6:146–151. http://dx.doi.org/10.1038/ng0294-146 PMid:8162068
Shimizu K, Ichikawa H, Tojo A, Kaneko Y, Maseki N, Hayashi Y et al. An ets-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc Natl Acad Sci USA. 1993;90:10280–10284. http://dx.doi.org/10.1073/pnas.90.21.10280 PMid:8234289 PMCid:PMC47758
Panagopoulos I, Aman P, Fioretos T, Hoglund M, Johansson B, et al. Fusion of the FUS gene with ERG in acute myeloid leukemia with t (16; 21) (p11; q22). Genes Chromosomes Cancer. 1994;11:256–262. http://dx.doi.org/10.1002/gcc.2870110408 PMid:7533529
Eid MA, Attia M, Abdou S, El-Shazly SF, Elahwal L, Farrag W et al. BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis. International Journal of Laboratory Hematology. 2010;32:197–205. http://dx.doi.org/10.1111/j.1751-553X.2009.01168.x PMid:19555438
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100: 2292-2302. http://dx.doi.org/10.1182/blood-2002-04-1199 PMid:12239137
Preisler H, Davis RB, Kirshner J, Dupre E, Richards F 3rd, Hoagland HC et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 1994;69:1441-1449.
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive post remission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903. http://dx.doi.org/10.1056/NEJM199410063311402 PMid:8078551
Balatzenko G, Stoimevov A, Guenova M, Nikolova V, Toshkov S. Incidence of BAALC gene over-expression in acute myeloid leukemia subtypes as defined by the World Health Organization classification. Haematologica. 2008;93(s1):407.
Heuser M, Berg T, Kuchenbauer F, Lai CK, Park G, Fung S et al. Functional role of BAALC in leukemogenesis. Leukemia. 2012;26: 532–536. http://dx.doi.org/10.1038/leu.2011.228 PMid:21869843
Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116: 5660–5669. http://dx.doi.org/10.1182/blood-2010-06-290536 PMid:20841507 PMCid:PMC3031412
Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C. BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia. Blood Cancer Journal. 2014; 4: e173. http://dx.doi.org/10.1038/bcj.2013.71 PMid:24413067 PMCid:PMC3913940
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
